Status:
UNKNOWN
Transcranial Direct-current Stimulation (tDCS) Efficacy in Refractory Cancer Pain.
Lead Sponsor:
Elsan
Conditions:
Cancer Pain
Refractory Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pain is a common symptom in palliative care cancer patients and is often insufficiently relieved. The 2010 INCA report showed that France is not an exception to this worldwide observation (synopsis of...
Detailed Description
tDCS appears to be more suitable than rTMS for the treatment of palliative care patients, who are often difficult to mobilize, as tDCS can be delivered at the patient's bedside and possibly even at ho...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patient with a confirmed cancer at a palliative stage
- Pain whose mean intensity is greater than or equal to 4/10 in the 48 hours preceding inclusion
- Pain present on a daily or almost daily basis (at least 4 days out of 7)
- Pain that has been present for at least 48 hours before inclusion
- Patients aged 18 or over
- Patients who can be followed for the duration of the study (i.e. 3 weeks)
- Patients affiliated to a health insurance plan or entitled
- Life expectancy estimated at more than 3 weeks
- Agreeing to participate in the study and having signed an informed consent
- Exclusion criteria
- Inability to self-assess pain and complete self-questionnaires
- History of head trauma or neurosurgical injury
- Symptomatic intracranial hypertension (HTIC)
- Uncontrolled epilepsy
- Impossibility to correctly positioning the medical device
- Abuse of drugs or psychoactive substances, at the discretion of the investigator
- Current major depression or psychosis
- Pregnant or breastfeeding woman
- Patient already included in a research protocol on pain
- Patient under legal protection
- Absence of affiliation to a social security scheme
- Specific contraindication to tDCS (intracerebral metal implant)
- Patients deprived of liberty
- Patients undergoing psychiatric care.
Exclusion
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04683172
Start Date
May 15 2021
End Date
June 15 2024
Last Update
September 14 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Brétéché
Nantes, France, 44000
2
CHU Nantes
Nantes, France, 44093